Cy­cla­cel pulls the plug on Dai­ichi-part­nered chemo — 8 years af­ter a failed PhI­II in AML

Hov­er­ing around pen­ny stock ter­ri­to­ry, New Jer­sey-based Cy­cla­cel Phar­ma­ceu­ti­cals $CY­CC said yes­ter­day it’s fi­nal­ly go­ing to call it quits on a Dai­ichi Sankyo-part­nered can­cer drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER